A 3-prong approach to disease control
Most early-stage biotechs ask investors to wait a decade for one binary outcome. Viropin pairs an earlier product with a long-term therapeutic, and partnerships that take both to market.
-

CONTROLLING INFECTIONS
Stopping resistant infections before they take hold, led by a nasal decoloniser built on our lead compound ZDR143.
Hospital-acquired infections extend patient stays, drive up healthcare costs, and accelerate the spread of antimicrobial resistance. Viropin develops a suite of infection-control products designed for the settings where the risk is highest: surgical units, intensive care, aged care, and high-throughput hospital environments.
Our product line includes:
MRSA nasal decolonisation: targeting one of the most persistent and costly sources of hospital infection.
Topical decolonisation therapies: protecting patients identified as carriers before admission, surgery, or transfer.
Pre-surgical scrubs: reducing surgical site infection risk at the point of greatest vulnerability.
Hospital antiseptics and environmental sanitation: supporting infection-control protocols across the patient journey.
These are practical, deployable products. They use familiar regulatory pathways, address pain points hospital procurement teams already budget for, and reach market years ahead of any therapeutic.
-

RESTORING ANTIBIOTICS
Making existing antibiotics work again.
Many antibiotics fail not because they are ineffective, but because bacteria have evolved mechanisms to block or evade them. Rather than chase the costly and uncertain pursuit of entirely new antibiotic classes, Viropin's therapeutic platform disrupts these resistance mechanisms, restoring the potency of antibiotics already approved, manufactured, and familiar to clinicians worldwide.
This approach is faster to clinic, lower risk to develop, and immediately useful at scale. It extends the useful life of treatments hospitals already rely on, and gives healthcare systems a practical tool against the most dangerous resistant infections.
Our lead therapeutic programme moves through lead identification from 2027 to mid-2028 and non-clinical development to the end of 2029, with a Phase 1 clinical trial planned for 2030.
-

GLOBAL EXPANSION
Taking both to the world through partnership.
Strategic partnerships open clinical development, regulatory access and distribution across North America, Europe, Asia and the Middle East.
Working with regional pharmaceutical companies and healthcare leaders de-risks market entry and shortens the path into hospitals. The infection-control products build the commercial relationships that the therapeutic programme will later use.